Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines

Model scores of the 29,894 trials active now.

Model score 2% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (876 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-11-21. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: primaryprotocolmonthsprecedinghepatitis
  Phrases that lowered it: vaccineof agehealthyvaccinationmeningococcal
• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Sponsor's past termination rate: 4.1% (lowers risk) · Sponsor's track record
• Primary purpose: prevention (lowers risk) · Design
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor's past trials: 960 (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 465 (raises risk) · Sponsor's track record
• Number of arms: 4 (lowers risk) · Design
• Blinding: none (lowers risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Maximum age: 6.33 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 80% (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 20% (lowers risk) · Drug's FDA history
• Disease area, infectious disease: Yes (lowers risk) · Disease area
• Design: parallel (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination NCT01777308 · started 2013 · scored riskier than 2% of active trials completed
• Assessment of Antibody Persistence in Children Previously Vaccinated With Pneumococcal Conjugate Vaccine NCT00624819 · started 2008 · scored riskier than 2% of active trials completed
• The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers NCT00718666 · started 2008 · scored riskier than 2% of active trials completed
• The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Adolescents/Adults NCT00715910 · started 2008 · scored riskier than 2% of active trials completed
• Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose NCT01119625 · started 2010 · scored riskier than 1% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.